Back to search
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Clinicaltrials.gov:
EudraCT:
Other:
#79635322MMY2002
Other:
#2025
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Multiple Myeloma
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
Placebo
Ramantamig
Tocilizumab
Age
18+ years old
Biological sex
All
Placebo?
Yes
Trial start date
June 30, 2026
Trial end date
November 8, 2030
CT.gov ID
#NCT07589634
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Argentina,
- Australia,
- France,
- Greece,
- Malaysia,
- Portugal,
- Spain,
- Sweden,
- United States
Loading...
Enrolling
Athens, Greece, 115 25
Enrolling
Uppsala, Sweden, 752 37
Enrolling
Athens, Greece, 11528
Enrolling
Beverly Hills, California, United States, 90211
Enrolling
Nantes, France, 44000
Enrolling
Argenteuil, France, 95107
Enrolling
Bayonne, France, 64100
Enrolling
Le Mans, France, 72100
Enrolling
Irvine, California, United States, 92618
Enrolling
Goodyear, Arizona, United States, 85338
Enrolling
Denver, Colorado, United States, 80218
Enrolling
Concord, Australia, 2139
Enrolling
Falun, Sweden, 791 82
Enrolling
Rio, Greece, 265 04
Enrolling
Thessaloniki, Greece, 54642
Enrolling
Lisbon, Portugal, 1998 018
Enrolling
Valencia, Spain, 46017
Enrolling
Madrid, Spain, 28046
Enrolling
Pamplona, Spain, 31008
Enrolling
Buenos Aires, Argentina, C1118
Enrolling
Ampang, Malaysia, 68000
Enrolling
Buenos Aires, Argentina, C1199ABB
Enrolling
Córdoba, Argentina, X5016KEH
Enrolling
George Town, Malaysia, 10450
Enrolling
Kota Kinabalu, Malaysia, 88586
Enrolling
Johor Bharu, Malaysia, 80100
Enrolling
Buenos Aires, Argentina, C1426ANZ
Enrolling
Stockholm, Sweden, 141 86
Enrolling
Gothenburg, Sweden, 413 45
Enrolling
Kuching, Malaysia, 93586
Enrolling
Lund, Sweden, 221 85
Enrolling
Thessaloniki, Greece, 546 39
Enrolling
Braga, Portugal, 4710 243
Enrolling
Porto, Portugal, 4050 342
Enrolling
Porto, Portugal, 4200 319
Enrolling
Alexandroupoli, Greece, 681 00
Enrolling
St Louis, Missouri, United States, 63110
Enrolling
Wollongong, Australia, 2500
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
Key links
© Johnson & Johnson and its affiliates 2026
